fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Common blood pressure drug may make leukemia more responsive to chemotherapy while protecting heart

Written by | 1 Jul 2024

Researchers from the University of Missouri School of Medicine found that a targeted gene therapy may make acute myeloid leukemia (AML) more sensitive to chemotherapy, while also protecting the heart… read more.

App to help doctors help patients with leukemia

Written by | 28 Jun 2022

lymphocytic leukaemia (CLL) will develop a serious infection or need early treatment for CLL. 10 percent of these risk dying within a month. In order to help these… read more.

Therapeutic target for aggressive blood cancer

Written by | 25 Apr 2022

A new study published today in the journal Genes & Development reveals a gene that normally suppresses the formation of tumours but is reprogrammed at the onset of acute promyelocytic… read more.

Genentech announces data at EHA 2021 reinforcing efficacy of Venclexta combinations in chronic lymphocytic leukemia and acute myeloid leukemia

Written by | 17 Jun 2021

Genentech, a member of the Roche Group announced the latest data from three pivotal Phase III studies of Venclexta (venetoclax) – CLL14, MURANO and VIALE-A – to be… read more.

Oral azacytidine significantly prolongs survival in acute myeloid leukemia

Written by | 3 Jan 2021

Article written by Bruce Sylvester Investigators from the QUAZAR trial report that treatment with oral azacytidine (CC-486), significantly improves survival in older patients, over age of 55, with… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.